Brain scans aim to unlock antidepressant secrets of bipolar drug
NCT ID NCT05060549
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 31 times
Summary
This study planned to use brain imaging (PET scans) to see how cariprazine (Vraylar) affects dopamine D3 receptors in people with bipolar depression. The goal was to learn how the medication eases depression, not to test a new treatment. However, the study was withdrawn before any participants were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR DEPRESSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
Conditions
Explore the condition pages connected to this study.